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Plasma exchange in focal necrotizing glomerulonephritis without anti.
GBM antibodies. To determine whether plasma exchange was of
additional benefit in patients treated with oral immunosuppressive
drugs for focal necrotizing glomerulonephritis (without anti-GBM anti-
bodies), we performed a randomized controlled trial with stratification
for renal function on entry. Forty-eight cases were analyzed, 25 in the
treatment group (plasma exchange, prednisolone, cyclophosphamide
and azathioprine) and 23 in the control group (drug therapy only). There
was no difference in outcome in patients presenting with serum creat-
mine < 500 mol/Iiter (N = 17), or> 500 rmolIliter but not on dialysis
(N = 12), all but one of whom had improved by four weeks. However,
patients who were initially dialysis-dependent (N = 19) were more
likely to have recovered renal function (P = 0.041) if treated with
plasma exchange as well as drugs (10 of 11) rather than with drugs alone
(3 of 8). Long-term follow-up showed that improvement in renal
function was generally maintained. The results of this trial confirm that
focal necrotizing glomerulonephritis related to systemic vasculitis re-
sponds well to immunosuppressive drugs when treatment is started
early, and suggest that plasma exchange is of additional benefit in
dialysis-dependent cases.
Focal necrotizing glomerulonephritis (FNGN) is a severe
form of glomerular inflammation which, if left untreated, usu-
ally progresses to end-stage renal failure in weeks or months—a
syndrome known as rapidly progressive glomerulonephritis
(RPGN) [1]. It is characterized pathologically by the presence
of segmental proliferative and necrotizing lesions of glomerular
capillaries associated, in most instances, with compression of
the glomerular tuft by cellular "crescents" [2]. The processes
leading to this pathological appearance are not fully under-
stood, but may involve both humoral and cellular autoimmune
mechanisms, and occur in a variety of clinical settings. The lack
of understanding of underlying mechanisms has hampered the
development of rational forms of treatment, which has gener-
ally depended on the use of cytotoxic drugs to control the
abnormal immune response and corticosteroids to reduce in-
flammation.
The recognition that RPGN could be caused by autoantibod-
ies to the glomerular basement membrane (anti-GBM disease or
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Goodpasture's syndrome) [3] led to the introduction of plasma
exchange (PE) [4], which allowed rapid removal of circulating
anti-GBM antibody before the effects of immunosuppressive
drugs developed. Current results using this approach demon-
strate greater improvement in renal function in Goodpasture's
syndrome [5] than that reported in earlier series [3]. Because of
the successful use of PE in anti-GBM disease, a similar thera-
peutic regimen was adopted in RPGN associated with other
diseases, especially Wegener's granulomatosis (WG) and mi-
croscopic polyarteritis (MP) [6]. The demonstration in these
patients of circulating autoantibodies to neutrophil cytoplasm
(ANCA) [7, 8], and more recently to glomerular and other
vascular endothelium [9—11], provides a further rationale for
this approach. Uncontrolled results suggested a benefit from
this form of treatment in systemic vasculitis [121, but as the use
of cyclophosphamide and steroids without PE was also re-
ported to be effective [13], a randomized controlled trial of the
use of PE (in addition to immunosuppressive drugs) was estab-
lished in 1978.
In this trial, we recruited patients with FNGN related to
systemic vasculitis within the spectrum of "polyarteritis" [14],
including those with idiopathic (I) RPGN [15, 16], but excluded
cases with other defined immunopathology. Patients were strat-
ified according to renal function at presentation, in order to
allow separate analysis of the response in patients with varying
severity of disease.
Methods
Patients
Patients with evidence of impaired renal function, renal
biopsy showing FNGN with crescents, and a clinical diagnosis
of WG, MP or IRPGN as previously described [15, 17, 18], were
considered as candidates for the trial. Patients with anti-GBM
disease and those with other defined causes of vasculitis (such
as systemic lupus erythematosus, Henoch-SchOnlein purpura)
were excluded, as were cases with evidence of underlying
chronic glomerulonephritis. Patients who had previously been
treated with intravenous methyiprednisolone, oral cyclophos-
phamide or PE were also excluded, although prior oral steroid
therapy was permitted.
Fifty-two consecutive patients fulfilling the diagnostic criteria
were stratified for severity into groups depending on renal
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function at the start of treatment. The most severe group was
categorized as "dialysis-dependent" rather than oliguric, since
this was a more practical approach. Criteria for starting dialysis
were conventional for acute renal failure and included oligo-
anuria, severe fluid overload or hyperkalemia, and serum
creatinine approaching 1000 mol/liter; these remained consis-
tent throughout the trial. Patients were allocated to treatment
(PE and drugs) or control (drugs alone) arms of the trial by
random numbers. Treatment was started within 24 hours of
clinical diagnosis. The randomization procedure ensured that
patients in different arms of the trial were equally distributed
throughout its course.
Investigations
All patients had initial standard hematological and biochem-
ical profiles, including tests of renal and hepatic function.
Creatinine clearance was estimated in cases not on dialysis. In
addition, complement C3, C4 and CH5O, and autoantibodies to
GBM and dsDNA were measured, in order to exclude anti-
GBM disease and systemic lupus erythematosus. Hepatitis B
surface antigen was not detected in any case. Renal biopsies
were processed for light and electron microscopy and direct
immunofluorescence, and reported by a single observer (DiE)
without knowledge of the clinical diagnosis or response to
treatment. Subsequently, renal function was monitored by
serum creatinine or creatinine clearance as clinically indicated,
with assessment points at one, 2, 6 and 12 months and annually
thereafter.
Treatment
It was not considered necessary to include a "sham" PE
treatment protocol. Control patients received induction therapy
to 8 weeks of: (1) prednisolone 60 mg daily, reducing by 15 mg
at weekly intervals to 30 mg daily, then by 5 mg at weekly
intervals to 20 mg daily, and subsequently more slowly as
clinically indicated; (2) cyclophosphamide 3 mg/kg daily; (3)
azathioprine 1 mg/kg daily. Patients over 55 years were given
cyclophosphamide 2 mg/kg daily and no azathioprine, because
of the increased risks of immunosuppression. Cytotoxic drugs
were temporarily discontinued if leucopenia (< 4 x 109/liter)
occurred, or in the presence of severe intercurrent infection.
After 8 weeks, cyclophosphamide was stopped in those patients
in remission and azathioprine dosage increased to 2 to 3 mg/kg
daily for maintenance therapy, together with tapering doses of
prednisolone. Treatment was normally continued for at least
one year, after which attempts were made to discontinue it.
The PE group received identical drug therapy, together with
at least five, 4 liter exchanges for 5% albumin (plasma protein
fraction, PPF) within the first week. Two units of fresh frozen
plasma (FFP) were given at the end of the exchange to restore
clotting factors only if there was overt haemorrhage, or within
48 hours of renal biopsy or surgery. Fresh plasma was used
infrequently and in small volumes, so a separate analysis of its
effect was not possible. The total number of exchanges was
determined by the clinical response, and a mean of nine
procedures was performed (range 5 to 25). Vascular access was
achieved by cannulation of antecubital veins whenever possi-
ble; central venous cannulation was sometimes required and
rarely arterio-venous shunts were used. All plasma exchanges
Table 1. Patients analyzed in the trial
Treatment (25) Control (23)
Age years 18—76 (52) 14—69 (51)
Sex (M:F)
Diagnosis (WG:MP:I)
16:9
10:11:4
14:9
13:9:1
were performed on a discontinuous-flow cell centrifuge (He-
monetics).
Definition of improvement
This was defined as a fall in serum creatinine of> 25% (or a
rise in creatinine clearance of> 25% in cases with initial serum
creatinine <150 LmolIliter) for patients not on dialysis at
presentation; and as recovery of renal function independent of
dialysis in those patients already on dialysis. In non-dialysis-
dependent patients, the change in serum creatinine was also
compared in each arm of the trial. This assessment was made at
one month from the start of treatment. Follow-up data were
obtained at 2, 6 and 12 months and then annually.
Statistical analysis
The difference in outcome at one month between patients in
each arm of the trial, in the three stratified groups, was
determined by a two-tailed Fisher's exact test. Numbers in the
trial, based on a preliminary analysis at five years [19], were
designed to avoid overlooking a 60% difference in response
between control and treated patients on dialysis, at a level of
significance of 5% using a test with a power of 95%. The degree
of improvement in renal function, in the groups not on dialysis,
was compared by analysis of co-variance using serum creati-
nine at presentation and at one month. The percentage of
crescents and of sclerosed glomeruli in the dialysis-dependent
groups was compared by the Mann-Whitney U test.
Results
The details of the analyzed cases are shown in Tables 1 and
2. The effect of treatment on renal function could not be
analyzed in four patients who died within two weeks. There
were two early deaths in the treatment group (lung hemorrhage
1, septicemia 1) and two in the control group (lung hemorrhage
1, septicemia 1), all occurring in patients who were dialysis-
dependent and gravely ill at presentation.
The outcome of the trial at one month is shown in Table 3.
There was no significant difference in outcome between treat-
ment and control arms for patients with initial creatinine <500
mol/liter or >500 pmol/liter, but a greater number of dialysis-
dependent cases treated with PE recovered renal function (P =
0.041, two-tailed Fisher's exact test). Analysis of co-variance
revealed no significant difference in the degree of recovery of
renal function at one month between treatment and control
groups of non-dialysis patients (Figs. 1 and 2).
There was no apparent difference in distribution between
treated and control patients with respect to age, sex or diagno-
sis, in any of the three strata of renal function. Renal biopsy
results are summarized in Table 4, and show similar findings in
treated and control patients at each level of renal function.
There was wide individual variation in histology, but both
groups contained comparable numbers of patients with the
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Treated patients
Cr < 500
M
M
F
M
F
M
M
M
M
Cr> 500
F
F
M
M
M
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M
F
M
F
M
F
F
M
M
F
M
Control patients
Cr < 500
F
M
F
M
F
F
M
M
Cr> 500
F
M
M
F
M
M
M
Dialysis dependent
F
M
M
F
F
WG
WG
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MP
343 IS! isoa
358 135 264
385 100 D
363 174 l67
130 122 409
141 109 106
336 198 133
239 124 l4l
310 150 119
975 160 970k
581 208 T
572 242 T
564 215 450k
636 155 147
1581(8) 445 811
815(6) 124 N/A
1842(1) 129 194
1138(1) 310 530
1405(2) 187 238
1250(1) 212 203
1084(13) D D
1752(4) N/A N/A
1310(1) — 600a
990(10) — 47l
735(1) — 376
384 81 97
368 339 D
447 220 T
488 274 672
95 81 90
321 80 107
445 138 T
359 — 592
— 7a
— 7
5 8
— 4a
— 8a
— 6
— 4
— 2a
— 8
I ia
9 11
3 10
— 7
— 3a
— 3a
— 8
— 8
— 6
— 3
0 4
— 3 (month)
— 2 (month)a
— 3 (month)a
— 2 (month)a
— 9
4 8
4 10
— 7
— 8
— 4
4 5
— 4 (month)a
— 6a
0
— 5
— 3
0 3 (month)a
0 1 (month)a
0 1 (month)a
0 1 (month)a
Myocardial infarct
I = P/A
Dialysis
Myocardial infarct
Cardiac failure
Independent
I = P/C
Pneumonia
Independent
Renal failure
Transplant
Transplant
Pneumonia
I = P/A
Myocardial infarct
Pulmonary embolus
I = P/A
IndependentI=A
I = P/A
Pneumonia
I = lost to follow-up
Lung hemorrhage
Septicemia
Pneumonia
I = P/A
D=A
Transplant
Independent
I = P/C
I = P/C
Transplant
Subarachnoid
Pneumonia
Renal failure
I = P/C
Independent
Pneumonia
Pneumonia
Myocardial infarct
Lung hemorrhage
same degree of histological damage. The dialysis-dependent none were detected (Tables 2, 4 and 5). In particular, there was
groups were examined closely for any differences in severity of no significant difference in the extent of crescent formation or
disease (including glomerular pathology) or management, and glomerulosclerosis between treatment and control groups.
Table 2. Long-term outcome of patients in the trial
Cr at
pres/ Time to Time of FU
Age at days on Cr at Cr current ESRF or to deatha
Sex presentation Diagnosis dialysis 1 year or at deatha years years/months Comment
MP
WG
MP
WG
WG
MP
MP
MP
55
71
18
70
60
36
47
69
46
30
37
26
68
62
61
59
52
68
54
66
23
39
39
76
73
43
63
60
47
48
55
48
37
14
45
35
67
16
53
65
58
69
51
53
54
60
56
66
WG
MP
MP
WG
WG
WG
WG
WG
WG
WG
MP
WG
WG
WG
MP
MP
WG
MP
MP
MP
WG
WG
WG
wG
MP
MP
WG
MP
WG
87 71
121 100
154 T
195 201
157 230
150 150
— 619
562
592
632
600
742
620
1100
NA(4)b
1629(1)
600(1)
803(0)
946(5)
909(1)
93 1(1)
442(0)'
— 10
— 9
4 10
— 4
— 5
— 4
— 1 (month)a
M
M
M
Independent
Independent
Transplant
IndependentI = P/A
1 = P/C
Lung hemorrhage
248
D
150
177
450a
150
150
Da
Da
Da
Da
Abbreviations are: D, dialysis; T, transplant; I, independent renal function; P, prednisolone; A, azathioprine; C, cyclophosphamide.
a Renal function at death or time to death
b No creatinine available before dialysis, value on transfer after 4 days was 338 imol/1iter
C Dialysis started for oliguria and fluid overload
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Table 3. Improvement in renal function at one month
Treatment (25) Control (23)
Creatinine <500 smol/liter
Creatinine >500 smol/liter
Dialysisdependenta
9/9
5/5
10/11
7/8
7/7
3/8
a P = 0.041, Fisher's exact test
6
Time, months
Fig. 1. Serial serum creatinine levels in patients presenting with cre-
atinine <500 pno!/liter. Symbols are: (0) died; (*) withdrawn from trial
and treated with PE.
Renal function was followed annually, and serial data to one
year for individual patients are shown in Figure 1 (creatinine <
500 smollliter), Figure 2 (creatinine >500 smol/liter) and Figure
3 (dialysis-dependent). The improvement in renal function
achieved in both treatment and control patients was generally
maintained. However, a further nine cases died between one
month and one year, three treatment and six control. The
principal causes of death in these patients with severe multisys-
tern disease were: treatment group—lung hemorrhage 1, pneu-
monia I, septicaemia 1; control group—lung hemorrhage 2,
pneumonia 2, myocardial infarction 1, subarachnoid hemor-
rhage 1.
Long-term follow-up of surviving patients (from 3 to 11 years)
0
0
1000
0 800
600
400
200
0
confirmed that successfully treated patients generally main-
tained independent renal function unless the disease relapsed.
Of patients followed for more than one year, eight developed
end-stage renal failure (treatment 4, control 4), at 1, 3, 5 and 9
years in the PE group and during the fifth year in all cases in the
control group. There were ten further deaths, unrelated to
active vasculitis, which was not surprising considering the age
of the patients. Details of the long-term outcome of individual
patients are given in Table 2.
Discussion
This trial was started in 1978 in order to determine whether
PE, a relatively new form of therapy at that time, would be of
additional benefit in patients with FNGN without anti-GBM
antibodies treated with cytotoxic drugs and steroids. The ex-
elusion of patients with other immunopathologically defined
forms of nephritis, such as systemic lupus erythematosus or
Henoch-Schonlein purpura, was justified by their differing
natural history and response to treatment. Unlike anti-GBM
disease, in which the introduction of PE improved the outcome
so considerably that we did not regard a controlled trial to be
appropriate, RPGN associated with systemic vasculitis was
reported to respond to drug therapy alone [13]. Since our early
A Treatment
400
200
I..
0
C
C
0
A Treatment
1000
800
600
400
200
0
1000
800
600
400
200
0
2 6
12
Time, months
Fig. 2. Serial serum creatinine levels in patients presenting with cre-
atinine > 500 jsmol/liter. Symbol 0 means the patient died.
12
12
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Table 4. Summary of renal biopsy findings
Glomerular pathology %
Treatment Control
<500 > 500 RDT<500 > 500 RDT
Circumferential crescents 13
(0—58)
44
(0—61)
56
(0—100)
20
(0—59)
21
(0—46)
38
(0—75)
Partial crescents 18
(0—33)
14
(5—24)
13
(0—41)
27
(10—42)
42
(31—60)
18
(10—30)
Total sclerosis 8
(0—23)
17
(0—59)
15
(0—67)
11
(0—63)
7
(0—15)
20
(0—50)
Partial sclerosis 24
(0—83)
2
(0—5)
6
(0—67)
15
(0—38)
5
(0—20)
12
(0—27)
All of above 63 77 90 73 75 88
Note: For each feature the mean percentage and range is shown in the different groups.
Treatment (11) Controls (8)
Age years 23—76 (55) 51-66 (58)
Sex (M:F) 6:5 5:3
Diagnosis (WG:MP:I) 5:4:2 4:3:1
Prior steroids (cases) 3 3
Dialysis before entry days 1—13 (4) 0—5 (2)
Dialysis after entry daysa 1—31 (11) 7—14 (II)
Crescents plus sclerosis % 60—100 (90) 40—100 (88)
observations suggested a possible role for PE in such cases,
especially in those with advanced disease [121, the trial was
designed to compare outcomes in groups of patients with
different degrees of renal impairment.
The decision to include patients with WG, MP and IRPGN
was based on their histological and immunopathological simi-
larities on renal biopsy, and on our experience of their response
to treatment. The recent review of RPGN by Couser [1]
supports this concept, and emphasises the close similarities
between "renal vasculitis" [201 and "idiopathic RPGN" [21].
There is increasing evidence that patients with FNGN, with or
without systemic vasculitis, show a similar response to immu-
notherapy when matched for renal function [22—25]. Although
we were unaware of the relevance of ANCA at the start of the
trial, it has now become clear that these autoantibodies are
detectable in the different diagnostic groups included [7, 8, 15,
161, providing further support for their similarity.
Uncontrolled studies of such patients have generally rein-
forced our initial impression of the value of PE in advanced
cases [26—28]. One recent controlled trial, however, failed to
show a benefit of PE in RPGN [29]. In this study, the patient
groups selected and treatment regimens were different to our
own, and cases were not stratified for renal function. Other
uncontrolled series have indicated that the use of high-dose
intravenous methylprednisolone may also be more effective
than conventional therapy in advanced disease [30—32]. Of note
is the recent study by Bolton and Sturgill, who found that 16 of
23 patients became independent of dialysis following pulse
methylprednisolone compared with 0 of 9 receiving various oral
agents [32].
The trial has taken 10 years to complete, during which time
there have been various improvements in management, includ-
ing new antibiotics and more advanced renal and respiratory
support techniques, though patients in both arms of the trial will
have benefited similarly. An important factor, when compared
with other trials [29], is that our study has been performed in a
single center with the same group of physicians supervising
treatment, thus ensuring similar management throughout, in-
cluding criteria for dialysis. Side-effects of PE were few and
generally minor, and technical difficulty never prevented treat-
ment. The trial was not designed to examine the effect of PE on
extra-renal manifestations of systemic vasculitis, because of
Table 5. Details of dialysis-dependent patients A Treatment
RDT
800
a In patients who recovered
600
400
200L
a)
E 0
RDT
a)
o 800
600
400
200
0
6 12
Fig. 3. Serial serum creatinine in patients who were dialysis-depen-
dent. 0 = died.
Time, months
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difficulties in assessment, but it was our impression that they
improved more rapidly when PE was used. The relatively high
overall mortality in the trial reflects the severity of disease in
cases referred to our unit.
The results show that patients not already on dialysis re-
sponded uniformly well to the immunosuppressive drug regi-
men used, perhaps because of the consistent use of cyclophos-
phamide. In this situation, it was not possible to show
additional benefit from the use of PE in terms of the proportion
of patients improving, the degree of improvement or the sub-
sequent need for dialysis. However, the mean percentage of
circumferential crescents was less in the control group with
creatinine> 500 mol/liter than in the corresponding treatment
group (Table 4); this could be obscuring a beneficial effect of
PE. It is of interest that patients with MP and IRPGN re-
sponded equally as well as those with WG, which has previ-
ously been shown to respond to drug regimens including
cyclophosphamide [33]. Other authors have recently reported
that a similar "aggressive" approach to treatment leads to
improved survival in patients with idiopathic RPGN and micro-
scopic renal vasculitis when compared retrospectively with
more conservatively treated cases [34—37J.
A significant short-term benefit of PE in dialysis-dependent
cases has been demonstrated for the first time, although num-
bers were small. There were several deaths within the first year,
making longer-term comparison difficult. However, our results
indicate a greater potential for recovery of renal function than
that generally accepted [1, 32]. Patients with different clinico-
pathological diagnoses appeared to respond in a similar way.
Interestingly, we have now observed short-term improvement
in 13 of 16 ANCA positive dialysis-dependent patients with
FNGN treated with PE, prednisolone and cyclophosphamide
since the end of the trial (Mason PD et al, unpublished obser-
vations). This is in contrast to anti-GBM disease, in which
dialysis-dependent cases rarely recover [5, 32, 38]. Although
the proportion of crescents on renal biopsy may provide a guide
to prognosis in untreated or less aggressively treated cases of
FNGN [39], we have observed good responses to PE and drugs
regardless of histological severity. It is acknowledged that the
mean number of sclerosed glomeruli (as opposed to crescents)
was slightly higher in the control group on dialysis, whereas the
mean number of active crescents was higher in the treated
group on dialysis (Table 4), but these differences were not
statistically significant and there was wide individual variation.
More detailed clinicopathological correlations in a larger group
of patients are to be published separately, but the relationship
between histological severity and clinical outcome was not
good in aggressively treated cases [401.
The mechanism of action of PE in these patients remains
unknown, although there are two major possibilities. First, it
could act by removal of humoral inducers of glomerulonephntis
such as immune complexes or autoantibodies. Circulating
and/or deposited immune complexes are generally reported in
between 1/3 and 2/3 of such cases [12, 41], but the inconsistency
of these findings has led to doubts as to their clinical relevance.
More recently, autoantibodies to a cytoplasmic constituent of
neutrophils and monocytes (ANCA) have been demonstrated in
a high proportion of patients with active WG [7, 42], MP [8] and
IRPGN [15]. It is possible that these [43, 44], or related
antibodies directed against endothelial cells [9—il], have a
pathogenic role in systemic vasculitis. Second, PE could act by
removal of inflammatory mediators responsible for tissue injury
in glomerular disease, for example, complement components,
fibrinogen or other coagulation factors [45, 46]. More specific
forms of immunotherapy are needed to assess these possibili-
ties.
This trial confirms that adequate oral immunosuppressive
therapy (with or without PE) results in a favorable initial
outcome in non-dialysis-dependent patients with FNGN, and
suggests an additional benefit of PE in dialysis-dependent cases.
Whether PE is more or less effective than high-dose intravenous
methylprednisolone in this situation has not been examined,
and this question could be addressed in further controlled
studies. Long-term follow-up of these patients indicates that the
initial improvement in renal function is generally maintained,
usually with the use of low-dose maintenance immunosuppres-
sive therapy, and strengthens the argument for an aggressive
approach to the investigation and treatment of patients with
severe glomerulonephritis.
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